Xenetic Biosciences, Inc. Launches Digital Corporate Communication Channels
Xenetic Biosciences Reports Phase 2 Data on Drug Candidate ErepoXen(R) for Anemia
Xenetic Biosciences Completes $3,000,000 Bridge Note Financing
Xenetic Biosciences Announces Board Change
Xenetic Biosciences to Hold Business Update Conference Call January 20th
Xenetic Biosciences Completes Enrollment of Second Cohort in Phase 2a Study with ErepoXen® for Anemia; Hemoglobin Levels Rise into Therapeutic Range over Time
Xenetic Biosciences CEO Delivers “2014 – The Year in Review” Update to Investors and Stakeholders
Xenetic Biosciences Announces OncoHist™ Preclinical Data to be Featured in a Poster Presentation at the American Society of Hematology Annual Meeting
Xenetic Biosciences Partner Completes Dosing of Second Cohort in Phase 2a Study of ErepoXen® in Patients with Chronic Kidney Disease on Dialysis
